Executive Summary
Key Points
- MGUS is defined by M-protein <3 g/dL, <10% clonal marrow plasma cells, and absence of myeloma-defining events (CRAB + SLiM)
- The 2014 IMWG SLiM biomarkers (≥60% marrow PCs, FLC ratio ≥100, >1 MRI focal lesion) allow MM diagnosis before end-organ damage
- MASS-FIX (MALDI-TOF mass spectrometry) has replaced immunofixation at Mayo Clinic since 2018, with IMWG endorsement
- In CKD, absolute FLC levels are almost always elevated — the ratio corrected for GFR (iStopMM intervals) is the diagnostic metric
- FLC is the primary screening test for AL amyloidosis; the monoclonal protein screen is the primary screening test for MGUS/MGRS/MM
- A nephrologist who identifies a monoclonal protein with unexplained renal disease should not assume innocent MGUS — renal biopsy is essential for MGRS
1. Two Questions, Two Tests
The free light chain assay and the monoclonal protein screen (SPEP/immunofixation/MASS-FIX) answer different clinical questions and are not interchangeable:
| Clinical Question | Primary Test | Why |
|---|---|---|
| Does this patient have AL amyloidosis? | Serum FLC (kappa, lambda, ratio) + immunofixation | AL is caused by a small, often undetectable clone producing amyloidogenic light chains. The M-protein may be <0.010 g/dL. The FLC ratio detects clonal excess regardless of intact Ig |
| Does this patient have MGUS, MGRS, or MM? | SPEP/MASS-FIX + immunofixation + quantitative Igs | These disorders are defined by intact immunoglobulin clone. The screen detects, identifies, and quantifies. FLC is an add-on for risk stratification |
Clinical Pearl
In AL amyloidosis, the free light chain is the pathogen — the amyloidogenic light chain directly deposits in tissue and directly kills cardiomyocytes. In MGUS/MM, the free light chain ratio is a surrogate marker of clonality. This distinction explains why a patient with AL can have a normal M-protein and catastrophic organ failure.
2. Free Light Chain Interpretation in CKD
2.1 Why Absolute FLC Levels Fail in CKD
Both kappa and lambda FLC are renally cleared. As GFR falls, both accumulate. Kappa (monomer, ~22.5 kDa) is more dependent on glomerular filtration and backs up proportionally more than lambda (dimer, ~45 kDa). By CKD Stage 3b, both are typically double the upper limit of normal. The lab flags both as "H" in essentially every CKD patient.
Warning
Ignoring the FLC result because "FLC is always high in CKD" is clinically rational but diagnostically dangerous. It is the exact cognitive trap that allows lambda AL amyloidosis to go undetected for months. Look at the ratio, not the absolutes. Apply the iStopMM renal-adjusted intervals.
2.2 Standard vs. Renal-Adjusted FLC Reference Ranges
| Analyte | Reference Range (mg/L) | Reference Range (mg/dL) | Notes |
|---|---|---|---|
| Free Kappa | 3.3–19.4 | 0.33–1.94 | Monomer (~22.5 kDa), filtered rapidly |
| Free Lambda | 5.7–26.3 | 0.57–2.63 | Dimer (~45 kDa), filtered more slowly |
| Kappa/Lambda Ratio | 0.26–1.65 | Ratio is unitless | |
2.3 iStopMM eGFR-Adjusted FLC Ratio Intervals
The Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study established these eGFR-based reference intervals from 6,461 participants with eGFR <60:
| eGFR (mL/min/1.73m²) | CKD Stage | iStopMM Adjusted Ratio | Standard Ratio False-Positive Rate |
|---|---|---|---|
| ≥60 | 1–2 | 0.26–1.65 | Appropriate |
| 45–59 | 3a | 0.46–2.62 | 9% flagged abnormal |
| 30–44 | 3b | 0.48–3.38 | Higher false-positive rate |
| <30 | 4–5 | 0.54–3.30 | Significant over-diagnosis |
Clinical Pearl
In a CKD Stage 3b patient with kappa/lambda ratio of 2.5, the standard range flags this as abnormal (>1.65), potentially triggering unnecessary workup. The iStopMM-adjusted range (0.48–3.38) correctly identifies this as normal for that renal function. For nephrologists, the renal-adjusted FLC ratio is essential to avoid false-positive diagnoses of LC-MGUS in CKD patients.
2.4 Absolute FLC Levels in CKD (iStopMM Data)
| eGFR Group | Median Kappa (mg/L) | Median Lambda (mg/L) | Median Ratio |
|---|---|---|---|
| ≥60 | 14.3 | 14.2 | 1.02 |
| 45–59 | 21.3 | 18.6 | 1.14 |
| 30–44 | 30.2 | 24.7 | 1.22 |
| <30 | 47.5 | 35.0 | 1.32 |
2.5 The dFLC in CKD: Use With Caution
The dFLC (involved minus uninvolved FLC) is the key staging metric for AL amyloidosis (Mayo 2012 threshold: ≥180 mg/L). In CKD, both chains are elevated from retention, which artificially inflates the dFLC. The practical hierarchy:
- Confirm clonality using the ratio (renal-adjusted)
- Once confirmed, use dFLC for staging with awareness it may be modestly inflated
- Use serial dFLC for treatment monitoring, comparing to the patient's own baseline
3. Kappa vs. Lambda Patterns
| Feature | Multiple Myeloma | AL Amyloidosis |
|---|---|---|
| Light chain predominance | Kappa (~60–65%) | Lambda (~70–75%) |
| Ratio direction | Usually high (kappa excess) | Usually very low (lambda excess) |
| Typical FLC pattern | High kappa or high lambda with abnormal ratio | Very high lambda (often >500 mg/L) with ratio near 0 |
| M-protein size | Often ≥1 g/dL; detectable on SPEP | Often small or absent on SPEP; FLC may be only marker |
| Bone marrow plasma cells | Usually ≥10%, often >30% | Typically <20% (smaller clone) |
| Organ involvement | CRAB features | Heart, kidney, nerve, GI, soft tissue |
| N-glycosylation on MASS-FIX | Uncommon | More common (independent risk marker) |
Clinical Pearl
Lambda light chains — particularly those encoded by the V-lambda-6 germline gene — are inherently more amyloidogenic (greater propensity to misfold into fibrils). Lambda AL is associated with cardiac and renal involvement. Kappa AL is less common but associated with hepatic involvement. When you see a lambda-predominant monoclonal protein with organ dysfunction, AL amyloidosis is in the differential until proven otherwise.
4. The MASS-FIX Panel
MASS-FIX (MALDI-TOF mass spectrometry) uses nanobody immunoenrichment and has replaced serum immunofixation at Mayo Clinic Rochester since 2018:
4.1 Panel Structure
| Code | Heavy Chain | Light Chain | Associated Condition |
|---|---|---|---|
| GK | IgG | Kappa | Most common MM/MGUS isotype (~50%) |
| GL | IgG | Lambda | MM/MGUS; lambda raises AL concern |
| AK | IgA | Kappa | Non-IgG = Mayo 2005 risk factor; beta-migrating on SPEP |
| AL | IgA | Lambda | Non-IgG risk factor; lambda raises AL amyloidosis differential |
| MK | IgM | Kappa | Progresses toward Waldenström macroglobulinemia, not MM |
| ML | IgM | Lambda | WM/lymphoplasmacytic lymphoma |
4.2 Advantages Over Conventional Methods
- Superior sensitivity for M-protein detection vs immunofixation
- Determines precise molecular mass — unique "fingerprint"
- Differentiates therapeutic monoclonal antibodies (daratumumab) from disease M-protein
- Detects light chain N-glycosylation (risk marker for AL amyloidosis)
- Now IMWG-endorsed as an alternative to immunofixation
Warning
Serial monitoring should use the same method at the same laboratory. Switching between gel SPEP, CZE, and MASS-FIX introduces variability that may be mistaken for disease progression or treatment response. Discrepancies of 0.3–0.5 g/dL between methods are clinically meaningful when they shift patients across the 3 g/dL threshold separating MGUS from SMM.
5. Risk Stratification Models
5.1 Mayo 2005 MGUS Risk Stratification
| Risk Factor | Threshold |
|---|---|
| M-protein concentration | ≥1.5 g/dL |
| Immunoglobulin isotype | Non-IgG (IgA, IgM, IgD) |
| Serum FLC ratio | Abnormal (<0.26 or >1.65) |
| Risk Group | Factors | 20-Year Progression Risk |
|---|---|---|
| Low | 0 | 5% |
| Low-Intermediate | 1 | 21% |
| High-Intermediate | 2 | 37% |
| High | 3 | 58% |
5.2 Mayo 2018 "20/2/20" for Smoldering Myeloma
| Risk Factor | Threshold |
|---|---|
| Bone marrow plasma cells | >20% |
| Serum M-protein | >2 g/dL (20 g/L) |
| Serum FLC ratio | >20 |
5.3 SLiM Myeloma-Defining Events
| Biomarker | Definition | 2-Year Progression Risk |
|---|---|---|
| Sixty percent plasma cells | ≥60% clonal bone marrow PCs | ~80% |
| Light chain ratio | Involved/uninvolved FLC ratio ≥100 (involved FLC ≥100 mg/L) | ~80% |
| MRI focal lesions | >1 focal lesion ≥5 mm on MRI | ~80% |
Warning
Any single SLiM biomarker, even without CRAB features, is sufficient to diagnose MM requiring treatment. Approximately 20% of patients previously classified as SMM are reclassified as MM under the 2014 criteria.
6. MGRS: The Nephrologist’s Disease
Monoclonal Gammopathy of Renal Significance (MGRS) describes renal disease caused by a monoclonal immunoglobulin from a clone that does not meet criteria for overt malignancy. The key challenge: these patients have M-protein that looks like MGUS by every staging metric.
Clinical Pearl — The Two-Question Rule
- Is the kappa/lambda ratio abnormal for this patient's GFR? Use iStopMM intervals. If normal: FLC elevation is physiologic. If abnormal: go to question 2.
- What is the direction, and does it match the organ dysfunction?
- Very low ratio (lambda excess) + cardiac/renal/neuro dysfunction → AL lambda amyloidosis evaluation immediately
- Very high ratio (kappa excess) + nephrotic proteinuria → kappa AL or LCDD
- Mildly abnormal ratio + no organ dysfunction → LC-MGUS; risk-stratify and monitor
FLC Patterns by MGRS Entity
| MGRS Entity | Typical FLC Pattern | Ratio Direction |
|---|---|---|
| AL amyloidosis (lambda) | Lambda markedly elevated, kappa modestly elevated | Very low (<0.2, often <0.1) |
| AL amyloidosis (kappa) | Kappa markedly elevated | Very high (>10, sometimes >100) |
| LCDD (kappa predominant) | Kappa elevated; lambda normal or mildly elevated | High (often >5) |
| MPGN/C3G with monoclonal Ig | Variable; mild FLC ratio abnormality | Mildly abnormal or near-normal |
| PGNMID | Often IgG3 kappa; mildly abnormal | Mildly elevated (kappa) |
7. Clinical Decision Framework by Scenario
| Scenario | Order | Key Metric |
|---|---|---|
| Unexplained restrictive CM / HFpEF in elderly | FLC + immunofixation (serum and urine) | Ratio (renal-adjusted); dFLC for staging |
| Unexplained nephrotic syndrome | FLC + immunofixation + kidney biopsy | Monoclonal screen to identify clone; FLC ratio for risk |
| Routine MGUS surveillance | SPEP or MASS-FIX + quantitative Igs + FLC | M-protein trend; FLC ratio for Mayo 2005 score |
| CKD with unexplained proteinuria | MASS-FIX + FLC + quantitative Igs | Apply renal-adjusted FLC ratio |
| CKD with elevated FLC on routine labs | FLC ratio (renal-adjusted) | If within renal range: physiologic. If outside: investigate |
| Known MGUS + new organ dysfunction | FLC + MASS-FIX + organ-specific workup | dFLC for amyloid staging; screen for progression |
8. Critical Unit Conversions
Warning: Unit Errors Kill
FLC is reported in mg/L at most reference labs but some US labs report mg/dL. 1 mg/dL = 10 mg/L. The IMWG myeloma-defining threshold of involved FLC ≥100 mg/L = 10 mg/dL. Misreading units can cause tenfold misinterpretation. Similarly, the dFLC threshold of 180 mg/L for AL staging = 18 mg/dL. Always verify reporting units.
| Threshold | In g/dL | In g/L | Significance |
|---|---|---|---|
| Mayo 2005 MGUS risk factor | ≥1.5 g/dL | ≥15 g/L | One of three progression risk factors |
| MGUS → SMM boundary | 3 g/dL | 30 g/L | IMWG diagnostic criterion |
| Mayo 2018 "20/2/20" | >2 g/dL | >20 g/L | SMM high-risk factor |
| SPEP detection limit | ~0.2–0.5 g/dL | ~2–5 g/L | Below this, SPEP cannot detect |
References
- Rajkumar SV, Dimopoulos MA, Palumbo A, et al. IMWG updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548. PubMed
- Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in MGUS. Blood. 2005;106(3):812-817. PubMed
- Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in MGUS. N Engl J Med. 2002;346(8):564-569. PubMed
- Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma. Blood Cancer J. 2018;8(6):59. PubMed
- Murray DL, Puig N, Kristinsson S, et al. Mass spectrometry for evaluation of monoclonal proteins: IMWG report. Blood Cancer J. 2021;11(2):24. PubMed
- Mills JR, Kohlhagen MC, Dasari S, et al. Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF MS. Clin Chem. 2016;62(10):1334-1344. PubMed
- Mellors PW, Dasari S, Kohlhagen MC, et al. MASS-FIX for detection of monoclonal proteins: cross-sectional study of 6315 patients. Blood Cancer J. 2021;11(3):50. PubMed
- Thorsteinsdottir S, Gislason GK, Aspelund T, et al. Defining new reference intervals for serum free light chains in CKD: iStopMM results. Blood Cancer J. 2022;12(9):133. PubMed
- Leung N, Bridoux F, Batuman V, et al. Evaluation of MGRS: IKGMG consensus report. Nat Rev Nephrol. 2019;15(1):45-59. PubMed
- Gertz MA. Immunoglobulin light chain amyloidosis: 2024 update. Am J Hematol. 2024;99(2):309-324. PubMed
- Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583-596. PubMed
- Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis. J Clin Oncol. 2012;30(9):989-995. PubMed
Amyloid Series Navigation
© Urine Nephrology Now | Amyloid Series
Andrew Bland, MD, MBA, MS